Podcasts about jacksonville

Master the art of diligent research, insightful reflection, and meticulous note-taking to preach with confidence and depth. Get a new website, unlimited custom graphics, & full-service podcast production services at https://IncreaseCreative.Co/HB Register for the Cutting It Straight Conference at https://HBCharlesJr.com Subscribe to the Cutting It Straight magazine at https://CISmag.org Connect with H.B. and access more resources at https://HBCharlesJr.com The On Preaching Podcast is dedicated to helping you to preach faithfully, clearly, and better. Hosted by H.B. Charles, Jr., Pastor-Teacher of Shiloh.Church in Jacksonville, Florida  Produced by Luke Clayton and the team at IncreaseCreative.Co

This week on Million Dollaz Worth of Game, Gillie & Wallo take a trip down south to visit the one and only Lil Duval at his newly purchased private 55-acre paradise; Camp Duval. With two lakes and tons of wildlife... This episode is packed with unforgettable moments. Watch as Gillie goes fishing for the first time, Wallo tries to catch a snake, and Lil Duval shows us what it means to live your best life.

Life isn't a playground- it's an arena. In this message, we unpack how the story of the Passover points us to the ultimate battle Jesus fought and won for us on the cross. From the first Exodus to the final victory at the empty tomb, you'll see how God steps in when we can't win the fight ourselves. Whether you're weary from your spiritual battles, feeling stuck in bondage or just need a reminder that God has never lost a fight, this message will help you stand firm and rest in the victory Jesus has already won. - The Church of Eleven22® is a movement for all people to discover and deepen a relationship with Jesus Christ. Eleven22 is led by Pastor Joby Martin and based in Jacksonville, Florida, with multiple campuses throughout Jacksonville and the surrounding areas. To find out more about how God is moving at Eleven22, go to CoE22.com

Today’s Best of Features: (00:00-13:09) – JP Shadrick from Jaguars.com is the next company camp caravan stop for Query & Company. Jake asks JP about the transition for Head Coach Liam Coan so far, where Trevor Lawrence is at mentally as he tries to learn his third different offense in his career, believes that Jacksonville will let Travis Hunter play both offense and defense, and shares what the Jaguars fans think of the Indianapolis Colts. (13:09-25:51) – Tim Benz from Tribune Sports in Pittsburgh joins Query & Company as Jake’s company camp caravan continues. Their conversation starts with Tim explaining why he isn’t buying into the Steelers being “all in” this season, thinks that the signing of Aaron Rodgers is comparable to them bringing Russell Wilson in a season ago, and shares what the perception of the Colts is within Pittsburgh. (25:51-52:32) – Tony East from Locked On Pacers and Forbes Sports joins the program to discuss the Myles Turner fallout. He explains why Turner would be so adamant on a fourth year on a contract offer with a player option being the fourth year and having a 15% trade kicker if he is traded by the Bucks. Jake also asks Tony about which of the three free agent centers could be back for next season, admits that he’s fascinated to see what the Pacers do this upcoming season from a transaction standpoint with money being the primary focus, and expresses some frustrations on how people are covering and creating narratives about the Fever.Support the show: https://1075thefan.com/query-and-company/See omnystudio.com/listener for privacy information.

(00:00-26:09) – Query & Company opens on a Thursday with Jake Query and producer Eddie Garrison discussing the passing of two legendary figures in the Indianapolis sports industry. Dave Calabro, formerly with WTHR, joins Jake Query in sharing stories about Don Hein following the announcement of his passing earlier today and what he learned from Hein as being the guy who was brought in to replace Hein when he retired. Additionally, Calabro comments on the passing of Dick Mittman. (26:09-39:54) – JP Shadrick from Jaguars.com is the next company camp caravan stop for Query & Company. Jake asks JP about the transition for Head Coach Liam Coan so far, where Trevor Lawrence is at mentally as he tries to learn his third different offense in his career, believes that Jacksonville will let Travis Hunter play both offense and defense, and shares what the Jaguars fans think of the Indianapolis Colts. (39:54-53:40) – The first hour of the program concludes with Jake and Eddie discussing the likelihood that the Indiana Pacers are going to bring back some collection of Isaiah Jackson, Thomas Bryant, and James Wiseman to go with Tony Bradley next season. (53:40-1:16:59) – Hour two of the program starts with Jake Query and Eddie Garrison debating whether the Indiana Pacers fandom is growing nationally following this postseason run. Eddie highlights something he heard on one of the local TV stations from a couple. Jake compares what the Pacers are experiencing right now from a national standpoint to the days when the Colts were on top of the NFL. (1:16:59-1:30:50) – Tim Benz from Tribune Sports in Pittsburgh joins Query & Company as Jake’s company camp caravan continues. Their conversation starts with Tim explaining why he isn’t buying into the Steelers being “all in” this season, thinks that the signing of Aaron Rodgers is comparable to them bringing Russell Wilson in a season ago, and shares what the perception of the Colts is within Pittsburgh. (1:30:50-1:38:43) – The second hour of today’s show wraps up with Jake discussing his July 4th plans. He also pays tribute to Don Hein and Dick Mittman after learning about their passing earlier today with those two being sports icons during the start of his professional career. (1:38:43-2:05:42) – Tony East from Locked On Pacers and Forbes Sports joins the program to discuss the Myles Turner fallout. He explains why Turner would be so adamant on a fourth year on a contract offer with a player option being the fourth year and having a 15% trade kicker if he is traded by the Bucks. Jake also asks Tony about which of the three free agent centers could be back for next season, admits that he’s fascinated to see what the Pacers do this upcoming season from a transaction standpoint with money being the primary focus, and expresses some frustrations on how people are covering and creating narratives about the Fever. (2:05:42-2:14:22) – Since there are no shows tomorrow on July 4th, Jake shares his Good For The Heart story brought to you by Franciscan Health! Today’s story features a store owner keeping his business going just for one specific customer to keep a tradition and daily routine going.Support the show: https://1075thefan.com/query-and-company/See omnystudio.com/listener for privacy information.

Brent Beaird of First Coast News in Jacksonville joins us to talk some college sports. Next we get into the NBA followed by the Big Number of the Day.

Condo prices are falling fast across the U.S.—especially in Florida—due to soaring HOA fees, rising insurance costs, and new special assessments. Sales dropped 12% year over year in May, while single-family home prices rose slightly. Florida and Texas are leading the decline, with several metros seeing price drops over 30%. Meanwhile, short-term rental investors are finding opportunity in NFL cities. Markets like Jacksonville, Cleveland, and Kansas City are posting strong STR revenue growth tied to football season demand. For investors, the key takeaway is that while condos are struggling, football-fueled STR markets are heating up. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode Summary Welcome to the art room today! In this episode of the Autism Blueprint Podcast, host Janeen Herskovitz welcomes Kelly DeSousa, a skilled art therapist from Jacksonville, Florida. Together, they explore the transformative power of art therapy, its methodologies, and its unique support for the neurodivergent population. This heartfelt episode is a celebration of […] The post Art Therapy | Exploring the Benefits for Neurodivergent Individuals | A conversation with Kelly DeSousa appeared first on Puzzle Peace Counseling.

Unlock the secrets to effective time management for ministry and beyond, mastering sermon preparation and life's demands with these nine proven strategies. Discover how to prioritize, schedule strategically, and cultivate a disciplined approach that fuels both productivity and spiritual well-being. Get a new website, unlimited custom graphics, & full-service podcast production services at https://IncreaseCreative.Co/HB Register for the Cutting It Straight Conference at https://HBCharlesJr.com Subscribe to the Cutting It Straight magazine at https://CISmag.org Connect with H.B. and access more resources at https://HBCharlesJr.com The On Preaching Podcast is dedicated to helping you to preach faithfully, clearly, and better. Hosted by H.B. Charles, Jr., Pastor-Teacher of Shiloh.Church in Jacksonville, Florida  Produced by Luke Clayton and the team at IncreaseCreative.Co

On this episode of The Drive & Dish NBA podcast, hosted by Kevin Rafuse (@rafusetolose) and Justin Cousart (@JustinContheAir), the guys start the show by talking the Celtics making a pair of trades, sending Kristaps Porzingis to Atlanta and Jrue Holiday headed to Portland. If we expect to see Boston continuing to make moves and what we expect the East to look like next year amid a ton of shakeups. Plus some bonus Warm Up Jumpers as Justin defends Jacksonville from an article that said it was the most boring city in America. Next, the guys talk all things NBA Draft. Cooper Flagg goes #1 and Dylan Harper goes #2. What type of impact can we expect from them right away? The guys talk other picks they like including for Philly, Sacramento and OKC. Plus, Ace Bailey's gamble backfires as he heads to Utah and a a look at why the Pelicans may have made a massive blunder regarding their pick next year. In Who's Ballin Who's Fallin, Naz Reid gets paid by the Timberwolves, Masai Ujiri is out in Toronto in a big shift and the NBA draft sells out to State Farm. Finally, another round of Immaculate Grid. Listen to the show wherever you get your podcasts and watch the show on YouTube!

Welcome to The Daily, where we study the Bible verse by verse, chapter by chapter, every day. Today's shout-out goes to Michael Mitchell from Jacksonville, FL. Your partnership with us through Project23 helps keep God's Word at the center of lives around the world. This one's for you. Our text today is Mark 9:9-13: And as they were coming down the mountain, he charged them to tell no one what they had seen, until the Son of Man had risen from the dead. So they kept the matter to themselves, questioning what this rising from the dead might mean. And they asked him, "Why do the scribes say that first Elijah must come?" And he said to them, "Elijah does come first to restore all things. And how is it written of the Son of Man that he should suffer many things and be treated with contempt? But I tell you that Elijah has come, and they did to him whatever they pleased, as it is written of him." — Mark 9:9-13 The mountaintop moment is over. And as Jesus, Peter, James, and John descend, Jesus gives them strict orders: "Tell no one—until the Son of Man has risen from the dead." What a strange instruction. You've just seen a divine vision—and now you're told to stay silent? But Jesus isn't hiding the truth. He's timing it. Some revelations only make sense after the resurrection. The disciples obey—maybe because they just heard the audible voice of God. But they're confused: “Rising from the dead?” they whisper. “What does that even mean?” Then comes the question that shows their hope and misunderstanding: “Why do the scribes say Elijah must come first?” They were still hoping for a victorious Messiah—one who would conquer, rule, and restore. They knew Malachi 4 said Elijah would come before the “great and awesome day of the Lord.” But they didn't realize that day would come through suffering, not strength. Jesus affirms that Elijah did come—John the Baptist filled that role. And how was he received? Rejected. Mocked. Killed. And Jesus makes it clear—the same will happen to him. The road to glory runs through grief. The path to resurrection winds through rejection. Rejection by the world doesn't mean rejection by God. It may mean you're right where you're supposed to be. Like the disciples, we want crowns without crosses. Glory without grief. But Jesus never promised that. He promised resurrection—and resurrection always follows death. So trust him in the mystery. Even when it hurts. Even when it's quiet. Even when it doesn't make sense. Because when God says, “Not yet,” He's not always saying, “Never.” He's just saying, “Wait—it's not time… yet.” #NotYetDoesntMeanNever, #TrustHisTiming, #Project23 ASK THIS: What “not yet” have you been hearing from God lately? How do you typically respond when God's plan confuses you? Have you ever experienced rejection while doing God's will? How can remembering Jesus' path through suffering change your perspective today? DO THIS: Write down one area in your life where God feels silent or slow. Pray over it today—and say aloud, “Not yet doesn't mean never.” PRAY THIS: Father, I trust you—even when I don't understand your timing. Help me follow Jesus through rejection and believe in the promise of resurrection. Amen. PLAY THIS: "Though You Slay Me"

Jacksonville native and Pulitzer Prize winning reporter Kevin Sack discusses his new history of the storied Charleston church.

In Week 4 of In The Arena, Pastor Joby takes us into Genesis 25 and 32 to unpack the story of Jacob — the deceiver who spent his whole life wrestling for control, until one night he found himself wrestling God Himself. Through Jacob's struggle, betrayal, and the wrestling match that changed his name to Israel, we see that real victory doesn't come by fighting God, but by finally surrendering to Him. If you've been fighting in your own strength, it's time to quit wrestling and truly win — by surrendering everything to the One who already wrestled death for you and won. - The Church of Eleven22® is a movement for all people to discover and deepen a relationship with Jesus Christ. Eleven22 is led by Pastor Joby Martin and based in Jacksonville, Florida, with multiple campuses throughout Jacksonville and the surrounding areas. To find out more about how God is moving at Eleven22, go to CoE22.com

Are your real estate deals falling apart because you're not mastering the art of negotiation and timing? In this episode of the Real Estate Excellence Podcast, Bobbie Jean DeMunck joins Tracy Hayes to unpack what it takes to thrive in today's volatile real estate market. With over 15 years in the business and a background in interior design and banking, Bobbie shares how blending aesthetics with strategy helps her listings stand out and sell faster—even in a slower market. She reveals her unique approach to negotiation, how she wins offers by shortening inspection periods and timelines, and why building strong relationships with inspectors, lenders, and other agents is key to closing. This episode is a masterclass for agents seeking to elevate their game with real-world tips on marketing, client psychology, and leveraging AI tools to stay ahead. If you're a real estate pro looking to upgrade your strategy or a buyer/seller wanting to navigate the market smartly, subscribe now and share this episode with a colleague or friend!   Highlights: 00:00–06:12 From Banking to Real Estate: Bobbie Jean's Journey Transitioning from a banking career into real estate Leveraging past experiences for success Discovering sales is about building trust How design and finance shaped her real estate style Learning to listen to what clients really want 06:13–14:01 Winning Strategies in Today's Housing Market Why timelines can make or break an offer Creating trust with clean and quick contracts Avoiding the “back on market” scenario Using home inspections to gain leverage Reading between the lines in buyer-seller motivations 14:02–21:05 Design, Decluttering, and Staging for the Win Using interior design to create buyer connection The power of removing distractions Helping clients understand market presentation How staging can affect appraisal value Creating emotional impact in showings 21:06–28:39 The Power of Vendor Relationships Building a reliable and fast-moving vendor list The importance of vendor-client-agent synergy Keeping transactions smooth with the right contacts Elevating client experience through preparedness When your reputation opens vendor doors 28:40–36:11 Using AI to Elevate Real Estate Marketing Writing listing descriptions with AI support Automating bios, captions, and social content Enhancing Google and SEO strategy through tech How AI helps agents work smarter, not harder Avoiding the common traps of lazy automation 36:12–01:20:18 Market Psychology, Buyer Hesitation & Agent Advice Explaining value over fear of high rates Handling “forever home” myths with clarity Empowering buyers to act in uncertain conditions What great agents do differently in communication Bobbie's final take on effort, presence, and professionalism   Quotes:  “Timeline is the most important thing—you win by tightening it.” – Bobbie Jean DeMunck  “If you listen to your buyers and sellers, you can usually figure out what they really want.” – Bobbie Jean DeMunck  “You're never too busy in life—it's what you choose to make time for.” – Bobbie Jean DeMunck  “I can walk into a house and immediately see what walls to knock down.” – Bobbie Jean DeMunck   To contact Edwina Burch, learn more about her business, and make her a part of your network, make sure to follow her on her Website and Instagram.   Connect with Bobbie Jean DeMunck! Website: https://bobbiejeanrealtor.com Twitter: https://x.com/demunckbj  Instagram: https://www.instagram.com/edwinaburch_/ YouTube: https://www.youtube.com/@BobbieJeanDeMunck LinkedIn: https://www.linkedin.com/in/bobbie-jean-demunck/   Connect with me! Website: toprealtorjacksonville.com   Website: toprealtorstaugustine.com    SUBSCRIBE & LEAVE A 5-STAR REVIEW as we discuss real estate excellence with the best of the best.   #RealEstateExcellence #JacksonvilleRealtor ##RealEstatePodcast #TopRealtorTips #RealEstateStrategy #InteriorDesignInRealEstate #TimelineNegotiation #HomeSellingTips #AIInRealEstate #FloridaRealtor #RealEstateMarketing #RealEstateExcellence #ListingAgentLife #RealEstateSuccess #JacksonvilleHomes #RealEstateDeals #RealtorMindset #NegotiationTips #HomeSellingStrategy #PonteVedraRealEstate #MarketShift2025 #RealtorRelationships

SummaryIn this episode of the Restaurant Owners Uncorked podcast, Wil interviews Don Nicol from TacoLu, discussing the challenges faced in the restaurant industry, including rising costs and labor issues. Don shares insights on maintaining customer experience, navigating cash flow, and the importance of community engagement. He reflects on the impact of events like the TPC tournament on business and his future plans for Taco Lou, including potential family involvement in the restaurant.Takeaways TacoLu is an iconic restaurant in Jacksonville, Florida. Rising costs in labor and food are significant challenges. Maintaining customer experience is crucial for success. Cash flow management is a learning curve for new restaurant owners. Events like the TPC tournament can significantly boost business. Building a brand involves community engagement and recognition. Don emphasizes the importance of not charging for chips and salsa. Family involvement in the restaurant can be a future consideration. The restaurant industry is constantly evolving with new challenges. Don enjoys the camaraderie and energy of working with his staff.

Built to Blast: The Rise of Moonshot Mark Built to Blast: The Rise of Moonshot Mark kicks off this power-packed episode featuring 13-year-old phenom Mark “Moonshot” Thompson. With SLIDE Field Reporters Lilah and Jake as co-hosts, Mark shares how he combines raw power, speed, and maturity to lead ZT National and inspire young athletes everywhere. Big Swings from Jacksonville to Fenway Born in Jacksonville, Florida, Mark plays for ZT National and attends St. Joseph's Catholic School. He’s earned his nickname the hard way—by blasting 21 home runs in just the spring season. From being raised on the ballfield to starring in elite events like Select Fest and Pitch, Hit & Run at Fenway Park, Mark is a rare mix of talent and humility. “Home runs aren't made—they come,” he explains, offering wisdom well beyond his years. A Multi-Sport Athlete with a Singular Focus While he still competes in basketball, football, and cross country, baseball is where Mark's heart is. He trains relentlessly—hitting four buckets of balls a day and refining his approach to go middle and oppo. His favorite bat? The OG Cat 9 Composite. Most overrated? The Icon. Off the field, Mark is just as dedicated—he's in the Honor Society and even won first in his science fair category. Mindset, Motivation, and the Moonshot Mentality Mark's maturity is part of what sets him apart. After struggling with emotions early in his career, he embraced failure as fuel for growth. “Greatness comes from failure, but failure makes greatness,” he says. Whether it's launching a 75-yard TD pass, competing against the nation's top hitters, or staying calm in clutch moments, Mark shows leadership that's rare at any age. Speed, Humility, and Dreams of The Show From learning under Blake Snell at Zilla to running a 13-minute two-mile and averaging 8–10 stolen bases a tournament, Mark proves he's more than a slugger. He dreams of being drafted—but only if it's first or second round. His backup plan? A full ride to play D1 baseball. His favorite player is Trey Turner, and his walkout songs—“TNT” by ACDC and “Calabria 2008”—reflect his explosive presence. “No moment is bigger than what you love. You gotta love the moment to be able to love the game.” – Mark “Moonshot” Thompson Check out Big Baller, Bigger Dreams and Bright Future featuring Brian Johnson Jr. for more elite youth athlete interviews. Learn more about Select Fest, one of the premier showcases for top youth baseball talent. Follow The SLIDE Podcast! Please email us with any questions or feedback. Help us grow by leaving a 5-star review and a question—we'll answer it on the show! You might even get the chance to co-host an episode. Email: TheSlidePodcastShow@gmail.com Website: www.theslidepodcastshow.com All Links: https://linktr.ee/theslidepodcastshow YouTube: https://www.youtube.com/@theslidepodcastshow Facebook: https://www.facebook.com/TheSlidePodcast Instagram: https://www.instagram.com/theslidepodcastshow/ TikTok: https://www.tiktok.com/@theslidepodcastshow?lang=en LinkedIn: https://www.linkedin.com/company/theslidepodcast X (Twitter): https://twitter.com/theslidepod

CBS47/FOX30 FIRST ALERT FORECAST– FRI. JUNE 27TH CHIEF METEOROLOGIST MIKE BURESH WOKV RADIO The WOKV Weather Meter for Today: 7 TODAY: Partly sunny with scattered afternoon showers & t'storms. High: 93 TONIGHT: A shower or storm early then partly cloudy. Low: 73 SATURDAY: Partly sunny with scattered afternoon showers & storms. High: 92 SUNDAY: Partly sunny with scattered afternoon showers & t'storms. High: 93 MONDAY: Partly sunny with scattered afternoon showers & t'storms. High: 92 TUESDAY: Partly sunny with scattered showers & t'storms. High: 91

Ryan Schmitt is CEO of Petticoat-Schmitt, a people-first site and utility based in Jacksonville, Florida. After a few jobs nearly took the company under in 2018. Ryan and his team set out on a journey to reimagine the way construction happens. Learn more by visiting their website and following Ryan on LinkedIn! https://www.petticoatschmitt.com/ https://www.linkedin.com/in/ryan-schmitt-14866587/ Learn more about attending the 2025 Ariat Dirt World Summit by visiting www.dirtworld.com! Questions or feedback? Email us at dirttalk@buildwitt.com!

What if your side hustle became your true calling? In this episode of the Real Estate Excellence Podcast, Tracy Hayes sits Edwina Burch. Edwina Burch is a dynamic Jacksonville real estate agent, shares her journey from aspiring attorney to becoming one of the top real estate agents in northeast Florida. Starting her career in education administration, Edwina transitioned to real estate after being inspired by a colleague's challenging real estate deal. Quickly realizing that selling real estate was not as simple as HGTV portrayed, Edwina embraced the challenge and soon achieved significant success by focusing on building authentic relationships and mastering the art of negotiation. Throughout the episode, Edwina emphasizes the importance of authenticity, consistency, and mindset in her career. She highlights pivotal decisions, such as hiring a transaction coordinator and leveraging social media effectively, which propelled her rapid rise in the industry.  Her story illustrates that with the right mindset, grit, and genuine connections, rapid success in real estate is attainable even for newcomers. Listen now to discover Edwina's secrets to quick and sustainable success in real estate. Don't forget to subscribe and leave a review if her story inspired you!   Highlights: 00:00–06:07 Intro & Career Beginnings Choosing Real Estate Over Law Moving to Jacksonville From Education to Real Estate First Brokerage Experience The Importance of Initial Training 06:08–13:54 Making the Shift to Full-Time Real Estate Realizing Real Estate Wasn't HGTV Building Initial Relationships First Transactions and Key Learnings Transitioning from Boutique Brokerage to Keller Williams Importance of Brokerage Choice 13:55–20:25 Strategies and Negotiations Learning to Negotiate Adapting to Market Changes Seller Pricing Strategies Buyer's Market Realities Challenges Competing with New Builds 20:26–26:00 Leveraging AI and Technology Adopting AI for Listing Descriptions AI Impact on Real Estate Searches Tech Integration in Business Utilizing LinkedIn and SEO Advantages of AI 26:01–36:45 Scaling with Support Importance of Transaction Coordinators How Support Staff Elevates Productivity Delegation for Success Interviewing the Right Coordinator Expanding Through Mentorship 36:46–01:15:54 Edwina's Secrets to Success Personality and Consistency Pivoting in Changing Markets Staying Authentic and Engaged Love for Real Estate and Community Creating Organic Connections   Quotes:  “Real estate was my calling, not law school. It should have been my goal at age 13 or 14.” – Edwina Burch  “It's all about relationships—authenticity always wins.” – Edwina Burch  “A good transaction coordinator is a game changer. They let you focus on income-producing activities.” – Edwina Burch  “You have to pivot in real estate; the market changes, and so must you.” – Edwina Burch   To contact Edwina Burch, learn more about her business, and make her a part of your network, make sure to follow her on her Website and Instagram.   Connect with Edwina Burch! Website: http://www.edwinaburchrealestate.com Instagram: https://www.instagram.com/edwinaburch_/   Connect with me! Website: toprealtorjacksonville.com   Website: toprealtorstaugustine.com    SUBSCRIBE & LEAVE A 5-STAR REVIEW as we discuss real estate excellence with the best of the best.   #RealEstateExcellence #JacksonvilleRealtor #RealEstateSuccess #JacksonvilleRealEstate #EdwinaBurch #RealEstatePodcast #RealEstateMindset #RealEstateTips #KellerWilliams #Authenticity #RealEstateStrategy #HomeBuying #HomeSelling #RealEstateLife #TransactionCoordinator #FirstTimeHomeBuyer #RealEstateCareer #RealEstateJourney #AgentLife #AIinRealEstate #BusinessGrowth #WomenInRealEstate

Send me feedback!Mayor Donna Deegan vetoed legislation yesterday that would prohibit the use of taxpayer funds for illegal immigrants. I break down why her vote was correct and detractors are wrong.SUPPORT THE SHOWLocals for $5/monthRumble Rants: Click green dollar sign during the showRumble Subscription: Click subscribe $5/monthHOW AM I DOING?Email: libertydadpod@gmail.comSHOW NOTESNews4Jax (Story)News4Jax (CM Diamond)Wait Song: Smoke RisingMusic by: CreatorMix.comVideo

CBS47/FOX30 FIRST ALERT FORECAST– THU. JUNE 26TH CHIEF METEOROLOGIST MIKE BURESH WOKV RADIO The WOKV Weather Meter for Today: 7 TODAY: Partly sunny with widely scattered inland (mainly near/west of I-95) this afternoon. High: 94 inland… 86-89 at the beaches. TONIGHT: Becoming mostly clear. Low: 72 FRIDAY: Partly sunny with a few afternoon showers & storms. High: 92 SATURDAY: Partly sunny with scattered afternoon showers & t'storms. High: 93 SUNDAY: Partly sunny with scattered afternoon showers & t'storms. High: 93 MONDAY: Partly sunny with scattered showers & t'storms. High: 92

Erik and Ant hit the Film Room this week to dive into the Bills' mixture of coverages, blitz plans and Keon Coleman's role in Year 2. Do we see any significant changes to the Bills' tendencies on defense with the new additions to the coaching staff?0:00 - Tyreek Hill Clip, Intro2:23 - Conversation on Tyreek Hill quote, Bills coverages7:55 - Bills' coverage rates graphic11:00 - Film Review: Bills in Quarters Coverage vs. Miami Dolphins14:40 - Film Review: Bills pattern matching vs. Miami Dolphins17:38 - Film Review: Bills in Cover 6 vs. miami Dolphins20:25 - Film Review: Bills post-snap Cover 3 vs. Miami Dolphins22:26 - Film Review: Bills show Cover 2 vs. Miami Dolphins26:13 - Film Review: Bills in Cover 2 vs. Miami Dolphins30:30 - Film Review: Bills rotate post-snap vs. Miami Dolphins, wrap-up on Hill conversation34:28 - Ryan Nielsen's detail with D-Line during minicamp37:25 - Film Review: Ryan Nielsen's D-Line games from Atlanta42:30 - Film Review: Ryan Nielsen's Interior from Jacksonville, wrap-up on Nielsen conversation47:13 - Keon Coleman's contested catch ability chart and discussion54:20 - Film Review: Keon Coleman's physicality57:00 - Film Review: Keon Coleman drop vs. Seattle Seahawks59:05 - Film Review: Keon Coleman drop vs. Baltimore Ravens, discussion wrap-up1:04:20 - Conversation on Bills' Offensive Line - is it elite?1:13:30 - Final thoughts, episode sign-offBuffaloBills #NFL #Billsmafia▶️ Hit subscribe for weekly X's & O's film sessions!

Dr. Vamsi Velcheti and Dr. Nate Pennell discuss novel treatment approaches in small cell and non-small cell lung cancer that were featured at the 2025 ASCO Annual Meeting. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host of the ASCO Daily News Podcast. I'm a professor of medicine and chief of hematology and oncology at the Mayo Clinic in Jacksonville, Florida. The 2025 ASCO Annual Meeting featured some exciting advancements in small cell lung cancer, targeted therapies for non-small cell lung cancer, and other novel [treatment] approaches. Today, I'm delighted to be joined by Dr. Nate Pennell to discuss some of the key abstracts that are advancing the lung cancer field. Dr. Pennell is the co-director of the Cleveland Clinic Lung Cancer Program and also the vice chair of clinical research at the Taussig Cancer Institute. Our full disclosures are available in the transcript of this episode. Nate, it's great to have you back on the podcast. Thanks so much for being here. Dr. Nate Pennell: Thanks, Vamsi. Always a pleasure. Dr. Vamsi Velcheti: Let's get started, and I think the first abstract that really caught my attention was Abstract 8516, “The Randomized Trial of Relevance of Time of Day of Immunotherapy for Progression-Free and Overall Survival in Patients With Non-Small Cell Lung Cancer.” What are your thoughts about this, Nate? Dr. Nate Pennell: I agree. I thought this was one of the most discussed abstracts, certainly in the lung cancer session, but I think even outside of lung cancer, it got some discussion. So, just to put this in perspective, there have been a number of publications that have all been remarkably consistent, and not just in lung cancer but across multiple cancer types, that immunotherapy, immune checkpoint inhibitors, are commonly used. And all of them have suggested, when looking at retrospective cohorts, that patients who receive immune checkpoint inhibitors earlier in the day – so in the morning or before the early afternoon – for whatever reason, appear to have better outcomes than those who get it later in the day, and this has been repeated. And I think many people just sort of assumed that this was some sort of strange association and that there was something fundamentally different from a prognostic standpoint in people who came in in the morning to get their treatment versus those who came later in the afternoon, and that was probably the explanation. The authors of this randomized trial actually decided to test this concept. And so, about 210 patients with previously untreated advanced non-small cell lung cancer were randomly assigned to get chemo and immune checkpoint inhibitor – either pembrolizumab or sintilimab – and half of them were randomly assigned to get the treatment before 3 PM in the afternoon, and half of them were assigned to get it after 3 PM in the afternoon. And it almost completely recapitulated what was seen in the retrospective cohorts. So, the median progression-free survival in those who got earlier treatment was 13.2 months versus only 6.5 months in those who got it later in the day. So, really enormous difference with a hazard ratio of 0.43, which was statistically significant. And perhaps even more striking, the median overall survival was not reached in the early group versus 17.8 months in the late group with a hazard ratio of 0.43, also highly statistically significant. Even the response rate was 20% higher in the early patients; 75% response rate compared to 56% in the late-time-of-day patients. So very consistent across all measures of efficacy with pretty good matched characteristics across the different groups. And so, I have to tell you, I don't know what to make of this. I certainly was a skeptic about the retrospective series, but now we have a prospective randomized trial that shows essentially the same thing. So, maybe there is a difference between getting treated in the morning, although I have yet to hear someone give a very good mechanistic explanation as to why this would be. What were your thoughts on this? Dr. Vamsi Velcheti: It's indeed fascinating, Nate, and I actually think this was a very interesting abstract. Really, I was caught off guard looking at the data. I mean, if it were a drug, we would be so excited, right? I mean, with those kind of survival benefits. I don't know. I think circadian rhythm probably has something to do with it, like different cytokine profiles at the time of administration. I mean, who knows? But I think it's a randomized trial, and I think I would expect to see a mad rush for treatment appointments early in the morning given this, and at least I want my patients to come in first thing in the morning. It'll be interesting to see. Dr. Nate Pennell: It's important to point out that in this study, everyone got chemo and immunotherapy. And, at least in our cancer center, most patients who are getting platinum-doublet chemotherapy and immunotherapy actually do get treated earlier in the day already, just because of the length of the infusion appointment that's needed. So it really is oftentimes people getting single-agent immunotherapy who are often getting the later, shorter visits. But if you have a choice, I think it would be very reasonable to have people treated earlier in the day. And I do think most of the impressions that I got from people about this is that they would like to see it reproduced but certainly well worth further investigation. And I personally would like to see more investigation into what the rationale would be for this because I still can't quite figure out, yes, if you got it at, say, you know, 5 PM, that's later in the day and I can understand that maybe your immune system is somewhat less receptive at that point than it would be in the morning. But because these checkpoint inhibitors have such long half-lives, it's still in your system the next morning when your immune system is supposedly more receptive. So I don't quite understand why that would be the case. Well, let's move on to the next study. I would like to hear your thoughts on Abstract 8515, “Plasma-Guided, Adaptive First-Line Chemoimmunotherapy for Non-Small Cell Lung Cancer.” Dr. Vamsi Velcheti: Yeah, this was another abstract that seems to be really interesting in my opinion. I think there's kind of a lot of emphasis lately on ctDNA and MRD-based assays to monitor disease. In the lung cancer space, we haven't had a lot of clinical trials looking at this prospectively, and this was one of those pilot studies where they looked at circulating free DNA (cfDNA)-based response-adaptive strategy for frontline patients who are PD-L1 positive. So, patients started with pembrolizumab monotherapy, and based on plasma molecular response after 2 cycles, those patients without response received early treatment intensification with a platinum doublet. So the approach essentially was to reduce the chemotherapy exposure in patients who respond to immunotherapy. And only about 17.5% of the patients on the trial received chemotherapy based on lack of molecular response. So, in this trial, what they found was patients with the cfDNA response had a markedly improved PFS of 16.4 months versus 4.8 months. So essentially, like, this is a really nice study to set a foundation on which we have to do larger studies to incorporate molecular markers trying to look at cfDNA response to inform treatment strategy, either escalation or de-escalation strategies. So, I thought it was a very interesting study. Dr. Nate Pennell: Yeah. I mean, we always have this question for patients, “Should they get immunotherapy alone or combined with chemo?” and I think this certainly is intriguing, suggesting that there may be ways you can monitor people and perhaps rescue those that aren't going to respond to single agent. I'd like to see a randomized trial against, you know, this strategy, perhaps against everyone getting, say, chemoimmunotherapy or make sure that you're not potentially harming people by doing this strategy. But I agree, it's time to move beyond just observing that cell-free DNA is prognostic and important and start using it to actually guide treatment. Dr. Vamsi Velcheti: Yeah, and I would just caution though, like, you know, I think we need more data, but, however, it's certainly a very interesting piece of data to kind of help inform future trials. So, there was another abstract that caught my attention, and I think this would be a very interesting abstract in the EGFR space. Abstract 8506, "Patritumab Deruxtecan (HER3-DXd) in Resistant EGFR-Mutant Advanced Non-Small Cell Lung Cancer Patients After Third-Generation EGFR TKI," it's the HERTHENA-Lung02 study. What do you think about the results of this study? Dr. Nate Pennell: Yeah, this was, I would say, very widely anticipated and ultimately a little disappointing, despite being a positive trial. So, these are patients with EGFR-mutant non-small cell lung cancer who have progressed after a third-generation EGFR TKI like osimertinib. This is really an area of major unmet need. We do have drugs like amivantamab in this space, but still definitely an area where essentially patients move from having a highly effective oral therapy to being in the realm of chemotherapy as their best option. So, this HER3 antibody-drug conjugate, patritumab deruxtecan, had some good single-arm data for this. And we're sort of hoping this would become an available option for patients. This trial was designed against platinum-doublet chemotherapy in this setting and with a primary endpoint of progression-free survival. And it actually was positive for improved progression-free survival compared to chemo with a hazard ratio of 0.77. But when you look at the medians, you can see that the median PFS was only 5.8 versus 5.4 months. It was really a modest difference between the two arms. And on the interim analysis, it appeared that there will not be a difference in overall survival between the two arms. In fact, the hazard ratio at the interim analysis was 0.98 for the two arms. So based on this, unfortunately, the company that developed the HER3-DXd has withdrawn their application to the FDA for approval of the drug, anticipating that they probably wouldn't get past approval without that overall survival endpoint. So, unfortunately, probably not, at least for the near future, going to be a new option for these patients. Dr. Vamsi Velcheti: Yeah, I think this is a space that's clearly an unmet need, and this was a big disappointment, I should say. I think all of us were going into the meeting anticipating some change in the standard of care here. Dr. Nate Pennell: Yeah, I agree. It was something that I was telling patients, honestly, that I was expecting this to be coming, and so now, definitely a bit of a disappointment. But it happens and, hopefully, it will still find perhaps a role or other drugs with a similar target. Certainly an active area. Well, let's leave the EGFR-mutant space and move into small cell. There were a couple of very impactful studies. And one of them was Abstract 8006, “Lurbinectedin Plus Atezolizumab as First-Line Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer, Primary Results from the Phase III IMforte Trial.” So, what was your impression of this? Dr. Vamsi Velcheti: Yeah, I think this is definitely an interesting study, and small cell, I remember those days when we had barely any studies of small cell at ASCO, and now we have a lot of exciting developments in the small cell space. It's really good to see. The IMforte trial is essentially like a maintenance lurbinectedin trial with atezolizumab maintenance. And the study was a positive trial. The primary endpoint was a PFS, and the study showed improvement in both PFS and OS with the addition of lurbinectedin to atezolizumab maintenance. And definitely, it's a positive trial, met its primary endpoint, but I always am a little skeptical of adding maintenance cytotoxic therapies here in this setting. In my practice, and I'd like to hear your opinion, Nate, most patients with small cell after 4 cycles of a platinum doublet, they're kind of really beaten up. Adding more cytotoxic therapy in the maintenance space is going to be tough, I think, for a lot of patients. But also, most importantly, I think this rapidly evolving landscape for patients with small cell lung cancer with multiple new, exciting agents, actually like some FDA-approved like tarlatamab, also like a lot of these emerging therapeutics like I-DXd and other ADCs in this space. You kind of wonder, is it really optimal strategy to bring on like another cytotoxic agent right after induction chemotherapy, or do you kind of delay that? Or maybe have like a different strategy in terms of maintenance. I know that the tarlatamab maintenance trial is probably going to read out at some point too. I think it's a little challenging. The hazard ratio is also 0.73. As I said, it's a positive trial, but it's just incremental benefit of adding lurbi. And also on the trial, we need to also pay attention to the post-progression second-line treatments, number of patients who received tarlatamab or any other investigational agents.  So I think it's a lot of questions still. I'm not quite sure I'd be able to embrace this completely. I think a vast majority of my patients might not be eligible anyway for cytotoxic chemotherapy maintenance right away, but yeah, it's tough. Dr. Nate Pennell: Yeah. I would call this a single and not a home run. It definitely is real. It was a real overall survival benefit. Certainly not surprising that a maintenance therapy would improve progression-free survival. We've known that for a long time in small cell, but first to really show an overall survival benefit. But I completely agree with you. I mean, many people are not going to want to continue further cytotoxics after 4 cycles of platinum-doublet chemo. So I would say, for those that are young and healthy and fly through chemo without a lot of toxicity, I think certainly something worth mentioning. The problem with small cell, of course, is that so many people get sick so quickly while on that observation period after first-line chemo that they don't make it to second-line treatment. And so, giving everyone maintenance therapy essentially ensures everyone gets that second-line treatment. But they also lose that potentially precious few months where they feel good and normal and are able to be off of treatment. So, I would say this is something where we're really going to have to kind of sit and have that shared decision-making visit with patients and decide what's meaningful to them. Dr. Vamsi Velcheti: Yeah, I agree. The next abstract that was a Late-Breaking Abstract, 8000, “Overall Survival of Neoadjuvant Nivolumab Plus Chemotherapy in Patients With Resectable Non-Small Cell Lung Cancer in CheckMate-816.” This was a highly anticipated read-out of the OS data from 816. What did you make of this abstract? Dr. Nate Pennell: Yeah, I thought this was great. Of course, CheckMate-816 changed practice a number of years ago when it first reported out. So, this was the first of the neoadjuvant or perioperative chemoimmunotherapy studies in resectable non-small cell lung cancer. So, just to review, this was a phase 3 study for patients with what we would now consider stage II or stage IIIA resectable non-small cell lung cancer. And they received three cycles of either chemotherapy or chemotherapy plus nivolumab, and that was it. That was the whole treatment. No adjuvant treatment was given afterwards. They went to resection. And patients who received the chemoimmunotherapy had a much higher pathologic complete response rate and a much better event-free survival. And based on this, this regimen was approved and, I think, at least in the United States, widely adopted.  Now, since the first presentation of CheckMate 816, there have been a number of perioperative studies that have included an adjuvant component of immunotherapy – KEYNOTE-671, the AEGEAN study – and these also have shown improved outcomes. The KEYNOTE study with pembrolizumab also with an overall survival benefit. And I think people forgot a little bit about CheckMate-816. So, this was the 5-year overall survival final analysis. And it did show a statistically and, I think, clinically meaningful difference in overall survival with the 3 cycles of neoadjuvant chemo-nivo compared to chemo with a hazard ratio of 0.72. The 5-year overall survival of 65% in the chemo-IO group versus 55% with the chemo alone. So a meaningful improvement. And interestingly, that hazard ratio of 0.72 is very similar to what was seen in the peri-operative pembro study that included the adjuvant component. So, very much still relevant for people who think that perhaps the value of those neoadjuvant treatments might be really where most of the impact comes from this type of approach. They also gave us an update on those with pathologic complete response, showing really astronomically good outcomes. If you have a pathologic complete response, which was more than a quarter of patients, the long-term survival was just phenomenal. I mean, 95% alive at 5 years if they were in that group and suggesting that in those patients at least, the adjuvant treatment may not be all that important.  So, I think this was an exciting update and still leaves very much the open question about the importance of continuing immunotherapy after surgery after the neoadjuvant component. Dr. Vamsi Velcheti: Yeah, I completely agree, Nate. I think the million-dollar question is: “Is there like a population of patients who don't have complete response but like maybe close to complete response?” So, would you like still consider stopping adjuvant IO? I probably would not be comfortable, but I think sometimes, you know, we all have patients who are like very apprehensive of continuing treatments. So, I think that we really need more studies, especially for those patients who don't achieve a complete CR. I think trying to find strategies for like de-escalation based on MRD or other risk factors. But we need more trials in that space to inform not just de-escalation, but there are some patients who don't respond at all to a neoadjuvant IO. So, there may be an opportunity for escalating adjuvant therapies. So, it is an interesting space to watch out for. Dr. Nate Pennell: No, absolutely. Moving to KRAS-mutant space, so our very common situation in patients with non-small cell lung cancer, we had the results of Abstract 8500, “First-Line Adagrasib With Pembrolizumab in Patients With Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer” from the phase 2 portion of the KRYSTAL-7 study. Why was this an interesting and important study? Dr. Vamsi Velcheti: First of all, there were attempts to kind of combine KRASG12C inhibitors in the past with immune checkpoint inhibitors, notably sotorasib with pembrolizumab. Unfortunately, those trials have led to like a lot of toxicity, with increased especially liver toxicity, which was a major issue. This is a phase 2 study of adagrasib in combination with pembrolizumab, and this is a study in the frontline setting in patients with the G12C-mutant metastatic non-small cell lung cancer. And across all the PD-L1 groups, the ORR was 44%, and the median PFS was 11 months, comparable to the previous data that we have seen with adagrasib in this setting. So it's not like a major improvement in clinical efficacy. However, I think the toxicity profile that we were seeing was slightly better than the previous trials in combination with sotorasib, but you still have a fair amount of transaminitis even in the study. At this point, this is not ready for clinical primetime. I don't think we should be using sotorasib or adagrasib in the frontline or even in the second line in combination with checkpoint inhibitors. Combining these drugs with checkpoint inhibitors in the clinical practice might lead to adverse outcomes. So, we need to wait for more data like newer-generation G12C inhibitors which are also being studied in combination, so we'll have to kind of wait for more data to emerge in this space. Dr. Nate Pennell: I agree, this is not immediately practice changing. This is really an attempt to try to combine targeted treatment with immune checkpoint inhibitor. And I agree with you that, you know, it does appear to be perhaps a little bit better tolerated than some of the prior combinations that have tried in this space. The outcomes overall were not that impressive, although in the PD-L1 greater than 50%, it did have a better response rate perhaps than you would expect with either drug alone. And I do think that the company is focusing on that population for a future randomized trial, which certainly would inform this question better. But in the meantime, I agree with you, there's a lot of newer drugs that are coming along that potentially may be more active and better tolerated. And so, I'd say for now, interesting but we'll wait and see. Dr. Vamsi Velcheti: Yeah, so now moving back again to small cell. So, there was a Late-Breaking Abstract, 8008. This is a study of tarlatamab versus chemotherapy as second-line treatment for small cell lung cancer. They presented the primary analysis of the phase III DeLLphi-304 study. What do you think about this? Dr. Nate Pennell: Yeah, I thought this was really exciting. This was, I would say, perhaps the most important lung study that was presented. Tarlatamab is, of course, the anti-DLL3 bispecific T-cell engager compound, which is already FDA approved based on a prior single-arm phase II study, which showed a very nice response rate as a single agent in previously treated small cell lung cancer and relatively manageable side effects, although somewhat unique to solid tumor docs in the use of these bispecific drugs in things like cytokine release syndrome and ICANS, the neurologic toxicities. So, this trial was important because tarlatamab was approved, but there were also other chemotherapy drugs approved in the previously treated space. And so, this was a head-to-head second-line competition comparison between tarlatamab and either topotecan, lurbinectedin, or amrubicin in previously treated small cell patients with a primary endpoint of overall survival. So, a very well-designed trial. And it did show, I think, a very impressive improvement in overall survival with a median overall survival in the tarlatamab group of 13.6 months compared to 8.3 months with chemotherapy, hazard ratio of 0.6. And progression-free survival was also longer at 4.2 months versus 3.2 months, hazard ratio of 0.72. In addition to showing improvements in cancer-related symptoms that were improved in tarlatamab compared to chemotherapy, there was actually also significantly lower rates of serious treatment-related adverse events with tarlatamab compared to chemotherapy. So, you do still see the cytokine release syndrome, which is seen in most people but is manageable because these patients are admitted to the hospital for the first two cycles, as well as a significant number of patients with neurologic side effects, the so-called ICANS, which also can be treated with steroids. And so, I think based upon the very significant improvement in outcomes, I would expect that this should become our kind of standard second-line treatment since it seems to be much better than chemo. However, tarlatamab is definitely a new drug that a lot of places are not used to using, and I think a lot of cancer centers, especially ones that aren't tied to a hospital, may have questions about how to deal with the CRS. So, I'm curious your thoughts on that. Dr. Vamsi Velcheti: Yeah, thank you, Nate. And I completely agree. I think the data looked really promising, and I've already been using tarlatamab in the second-line space. The durability of response and overall, having used tarlatamab quite a bit - like, I participated in some of the early trials and also used it as standard of care - tarlatamab has unique challenges in terms of like need for hospitalization for monitoring for the first few treatments and make sure, you know, we monitor those patients for CRS and ICANS. But once you get past that initial administration and monitoring of CRS, these patients have a much better quality of life, they're off chemotherapy, and I think it's really about the logistics of actually administering tarlatamab and coordination with the hospital and administration in the outpatient setting. It's definitely challenging, but I think it definitely can be done and should be done given what we are seeing in terms of clinical efficacy here. Dr. Nate Pennell: I agree. I think hospital systems now are just going to have to find a way to be able to get this on formulary and use it because it clearly seems to be more effective and generally better tolerated by patients. So, should move forward, I think. Finally, there's an abstract I wanted to ask you about, Abstract 8001, which is the “Neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone in resectable epidermal growth factor receptor-mutated non-small cell lung cancer: The NeoADAURA Study”. And this is one that I think was also fairly highly anticipated. So, what are your thoughts? Dr. Vamsi Velcheti: You know, I wasn't probably surprised with the results, and I believe we were all expecting a positive trial, and we certainly were handed a positive trial here. It's a phase III trial of osimertinib and chemotherapy or osimertinib in the neoadjuvant space followed by surgery, followed by osimertinib. It's a global phase 3 trial and very well conducted, and patients with stage II to stage IIIB were enrolled in the study. And in the trial, patients who had a neoadjuvant osimertinib with or without chemotherapy showed a significant improvement in major pathologic response rates over chemotherapy alone. And the EFS was also positive for osimertinib and chemotherapy, osimertinib monotherapy as well compared to chemotherapy alone. So overall, the study met its primary endpoint, and I think it sheds light on how we manage our patients with early-stage lung cancer. I think osimertinib, we know that osimertinib is already FDA approved in the adjuvant space, but what we didn't really know is how was osimertinib going to work in the neoadjuvant space. And there are always situations, especially for stage III patients, where we are on the fence about, are these patients already close to being metastatic? They have, like, almost all these patients have micrometastatic disease, even if they have stage III. As we saw in the LAURA data, when you look at the control arm, it was like a very short PFS. Chemoradiation does nothing for those patients, and I think these patients have systemic mets, either gross or micrometastatic disease at onset. So, it's really important to incorporate osimertinib early in the treatment course. And I think, especially for the locally advanced patients, I think it's even more important to kind of incorporate osimertinib in the neoadjuvant space and get effective local control with surgery and treat them with adjuvant. I'm curious to hear your thoughts, Nate. Dr. Nate Pennell: I am a believer and have long been a believer in targeted adjuvant treatments, and, you know, it has always bothered me somewhat that we're using our far and away most effective systemic therapy; we wait until after they go through all their pre-op treatments, they go through surgery, then they go through chemotherapy, and then finally months later, they get their osimertinib, and it still clearly improves survival in the adjuvant setting. Why not just start the osimertinib as soon as you know that the patient has EGFR-mutant non-small cell lung cancer, and then you can move on to surgery and adjuvant treatment afterwards? And I think what was remarkable about this study is that all of these patients almost - 90% in each arm - went to surgery. So, you weren't harming them with the neoadjuvant treatment. And clearly better major pathologic response, nodal downstaging, event-free survival was better. But I don't know that this trial is ever going to show an overall survival difference between neoadjuvant versus just surgery and adjuvant treatment, given how effective the drug is in the adjuvant setting. Nonetheless, I think the data is compelling enough to consider this, certainly for our N2-positive, stage IIIA patients or a IIIB who might be otherwise surgical candidates. I think based on this, I would certainly consider that. Dr. Vamsi Velcheti: Yeah, and especially for EGFR, like even for stage IIIB patients, in the light of the LAURA study, those patients who do not do too well with chemoradiation. So you're kind of delaying effective systemic therapy, as you said, waiting for the chemoradiation to finish. So I think probably time to revisit how we kind of manage these locally advanced EGFR patients. Dr. Nate Pennell: Yep, I agree. Dr. Vamsi Velcheti: Nate, thank you so much for sharing your fantastic insights today on the ASCO Daily News Podcast. It's been an exciting ASCO again. You know, we've seen a lot of positive trials impacting our care of non-small cell lung cancer and small cell lung cancer patients. Dr. Nate Pennell: Thanks for inviting me, Vamsi. Always a pleasure to discuss these with you. Dr. Vamsi Velcheti: And thanks to our listeners for your time today. You will find links to all of the abstracts discussed today in the transcript of the episode. Finally, if you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers:    Dr. Vamsi Velcheti   @VamsiVelcheti    Dr. Nathan Pennell   @n8pennell   Follow ASCO on social media:     @ASCO on Twitter     ASCO on Facebook     ASCO on LinkedIn   ASCO on BlueSky   Disclosures:   Dr. Vamsi Velcheti:   Honoraria: ITeos Therapeutics   Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus   Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Nathan Pennell:     Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron    Research Funding (Inst): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi 

Former Jacksonville journalist and politico Abel Harding tries his hand at fiction with the release of "Last Time I'll Ask."

Sermon from 6/22/2025 at Church of Our Saviour in Jacksonville, FL.

Ashton Holt's Testimony from 6/22/25 at Church of Our Saviour in Jacksonville, FL.

CBS47/FOX30 FIRST ALERT FORECAST– WED. JUNE 25TH CHIEF METEOROLOGIST MIKE BURESH WOKV RADIO The WOKV Weather Meter for Today: 8 TODAY: Mostly to partly sunny. High: 95 inland… 85-88 at the beaches. TONIGHT: Mostly clear. Low: 72 THURSDAY: Partly sunny with an isolated inland afternoon shower or t'storm. High: 93… 80s at the beaches. FRIDAY: Partly sunny with scattered afternoon showers & t'storms. High: 92 SATURDAY: Partly sunny with scattered afternoon showers & t'storms. High: 92 SUNDAY: Partly sunny with scattered showers & t'storms. High: 92

Excited to be joined by JP Acosta, staff writer at SB Nation covering both the NFL and college football. We kick things off with the NFL—J.P. breaks down how Jacksonville's new-look staff could reshape the franchise. We also dig into Michael Penix Jr.'s rookie tape, the impact of Frank Ragnow's surprise retirement in Detroit, and which NFL minicamp holdouts could shake up the NFL landscape.Then we shift to college football and J.P.'s preseason Big Ten power rankings. Why he put Oregon at No. 1, what gives Penn State the edge in 2025, and how big the red flags are at Ohio State and USC. We dive into breakout candidates like QB Aidan Chiles at Michigan State, the potential of QB Demond Williams at Washington, and the pressure on Lincoln Riley at USC.Plus, which team is most likely to outperform expectations, why Illinois at No. 4 raised some eyebrows—and what J.P. sees that others might miss. We also highlight 5 CFB transfers who could dramatically boost their 2026 NFL Draft stock.Don't miss this wide-ranging conversation with one of football media's sharpest voices.

Film-Makers Justin Graves and Byron Manuel talk about what it takes to make movies in 2025 being young, talented, and black. They talk about finding the dream of movies and giving up the dreams of music and sport.  They talk about doing what it takes on a budget, fundraising, festivals, developing a ton of projects, and getting their movie “Swoon” on Tubi. They also talk about being able to handle the gut punches that the business offers and keeping your spirits high. Bio: Justin Antuan Graves was born Nov 17, 1984. He is an American writer and producer. Born in Beaufort, South Carolina. A military brat his whole life, he moved around a lot and found comfort in watching movies and cartoons all day as a child, especially comedies. Everything from Honey, I Shrunk The Kids to Friday to Superbad and beyond gave him the passion and confidence to begin writing. Justin started his first screenplay in 2016 and in 2018 he made the move from Jacksonville, Florida to Los Angeles to pursue a career as a screenwriter. With no network, he made his own short films and content that eventually led to becoming a writer for comedians and influencers online such as Juhan Jones, Virgil Harris and Kassandra Lee. Justin is best known for What Had Happened Was (2020), Booty Call Chronicles (2019) and  most recently Swoon (2025) and Allure (2025). Justin is Co-President of On Script Pictures and is currently building a Hard R Comedy Film and TV slate with his partner Byron Manuel.Byron Manuel is a Writer, Producer, Director, and Filmmaker from Los Angeles. He expresses his passion for storytelling through a unique lens.  Byron got his start on critically acclaimed shows such as Showtime's "Kidding", HBO's "Euphoria", Disney's "KC Undercover", and "Run The World" on Starz, while simultaneously carving out his own lane as an Indie Filmmaker.

Chuck believes the full season start moving up to the current week zero is inevitable. Chuck and Heath discuss the building fan frustration at Auburn. Ryan Green of 1010 XL in Jacksonville looks at Florida's recent recruiting momentum.See omnystudio.com/listener for privacy information.

In this episode, Brett Cyphers sits down with Temperince Morgan, a fourth-generation Floridian who brings both personal roots and professional expertise to Florida's most pressing environmental issues. Temperince shares her story, beginning with her upbringing alongside a father with deep roots in ranching. Raised in Jacksonville and spending time with family in Lake Okeechobee, her love for nature was shaped by family trips around Florida. Her childhood was deeply connected to water and land—where cattle ranches, the St. Johns River, and Florida's state parks sparked a lasting bond with the landscape and laid the foundation for a career dedicated to its restoration and protection. She walks Brett through her time as a biology major at Florida State University and how that led to a career in environmental science. The conversation explores her roles at the Florida Department of Environmental Protection and the South Florida Water Management District, where she helped lead early efforts in Everglades restoration. Now, as Executive Director of The Nature Conservancy's Southern U.S. Division, she oversees large-scale environmental strategy across 10 states. They also dive into projects close to her, like the Pensacola East Bay Oyster Project. Rich in personal insight and professional depth, this episode offers an intimate look at one of Florida's most respected environmental leaders—and what it takes to protect the state's natural future. To explore the broader mission behind the work Temperince leads—conserving lands and waters across the U.S. and beyond visit The Nature Conservancy To hear more about the Florida-based initiatives Temperince references, including coastal resilience, water management, and Everglades restoration visit The Nature Conservancy in Florida To take a closer look at the project that Temperince highlights as an example of measurable, on-the-ground restoration visit Pensacola East Bay Oyster Project Temperince discusses values that are essential to future conservation success; this center reflects TNC's focus on science, outreach, and education. Find out more here Center for Conservation Initiatives As discussed in the episode, long-term land conservation is key to protecting Florida's water—to learn how TNC is doing it click here Florida Land Protection | The Nature Conservancy If Temperince's story inspired you, consider supporting the work she and her team are doing to build a more resilient Florida by visiting Donate Now to Protect Nature | The Nature Conservancy This episode is brought to you by our friends at Resource Environmental Solutions (RES). RES is the nation's leader in ecological restoration, helping to restore Florida's natural resources with water quality and stormwater solutions that offer communities guaranteed performance and outcomes. Check them out at www.res.us This episode is also brought to you by our friends at Sea and Shoreline. Sea and Shoreline is the Southeast's leading innovator in protecting coastal communities from devastating storms and restoring ecosystems that once faced ecological collapse. Visit their website at www.Seaandshoreline.com. Please be sure to check out the Florida Specifier Podcast hosted by Ryan Matthews and Brett as part of the environmental news and discussion brought to you by the Florida Specifier. To learn more about our flagship print publication, weekly newsletter and more, visit The Florida Specifier. You can follow the show on LinkedIn and Instagram @flwaterpod, and you can reach us directly at FLwaterpod@gmail.com with your comments and suggestions for who Brett should be talking with in the future. Production of this podcast is by Lonely Fox Studios. Thanks to Karl Sorne for making the best of what he had to work with. And to David Barfield for the amazing graphics and technical assistance.

CBS47/FOX30 FIRST ALERT FORECAST– TUE. JUNE 24TH CHIEF METEOROLOGIST MIKE BURESH WOKV RADIO The WOKV Weather Meter for Today: 8 TODAY: Mostly to partly sunny. High: 94 inland… 80s at the beaches. TONIGHT: Mostly clear. Low: 73 WEDNESDAY: Partly sunny with an isolated shower. High: 94… 80s at the beaches. THURSDAY: Partly sunny with widely scattered afternoon showers & t'storms. High: 92 FRIDAY: Partly sunny with a few showers & t'storms. High: 92 SATURDAY: Partly sunny with scattered showers & t'storms. High: 91

Between May and July of 2006, two women went missing from Jacksonville, Texas: Shaunte Coleman and Terri Reyes. According to an area newspaper, the women knew each other, but that wasn't the connection that made foul play seem incredibly likely. It was their connection to a disgraced policeman – one accused of rape and assault many times over – that garnered the most suspicion. That suspicion, however, was felt far more by the public than the police, since both Terri and Shaunte roamed some and had known drug issues. Because of that, police seemed reluctant to investigate the disappearances properly. When their remains were found, the investigation shifted to another police agency entirely.If you have any information about the deaths of Shaunte Mone Coleman or Terri Renee Reyes, please call the Nacogdoches county sheriff's office at 936-560-7794 or Texas Crime Stoppers at  800-252-8477.You can support gone cold and listen to the show ad-free at patreon.com/gonecoldpodcastFind us at https://www.gonecold.comFor Gone Cold merch, visit https://gonecold.dashery.comFollow gone cold on Facebook, Instagram, Threads, TikTok, YouTube, and X. Search @gonecoldpodcast at all or just click linknbio.com/gonecoldpodcastSources: Court Documents, The Tyler Morning Telegraph, The Jacksonville Daily Progress, and KETK TV. #JusticeForTerriReyes #JusticeForShaunteColeman #Jacksonville #JacksonvilleTX #TX #Texas #TrueCrime #TexasTrueCrime #ColdCase #TrueCrimePodcast #Podcast #ColdCase #Unsolved #Murder #UnsolvedMurder #UnsolvedMysteries #Homicide #CrimeStories #PodcastRecommendations #CrimeJunkie #MysteryPodcast #TrueCrimeObsessed #CrimeDocs #InvestigationDiscovery #PodcastAddict #TrueCrimeFan #CriminalJustice #ForensicFilesBecome a supporter of this podcast: https://www.spreaker.com/podcast/gone-cold-texas-true-crime--3203003/support.

In week three of In the Arena, Pastor Joby walks us through 1 Samuel 17 and the true meaning of the David and Goliath story. It's not about us being brave enough to slay our own giants. It's about a greater David, Jesus, who has already won the victory we could never win on our own. Whether you're staring down fear, addiction, brokenness, or doubt, the battle isn't yours to win—it's already been won at the cross. You don't need a cheerleader; you need a champion. And good news: you have one. - The Church of Eleven22® is a movement for all people to discover and deepen a relationship with Jesus Christ. Eleven22 is led by Pastor Joby Martin and based in Jacksonville, Florida, with multiple campuses throughout Jacksonville and the surrounding areas. To find out more about how God is moving at Eleven22, go to CoE22.com

After preaching nearly 90 sermons through the Gospel of Mark, H.B. shares the invaluable handful of resources that proved most faithful, providing the clearest insight and richest spiritual sustenance for the journey. Get a new website, unlimited custom graphics, & full-service podcast production services at https://IncreaseCreative.Co/HB Register for the Cutting It Straight Conference at https://HBCharlesJr.com Subscribe to the Cutting It Straight magazine at https://CISmag.org Connect with H.B. and access more resources at https://HBCharlesJr.com The On Preaching Podcast is dedicated to helping you to preach faithfully, clearly, and better. Hosted by H.B. Charles, Jr., Pastor-Teacher of Shiloh.Church in Jacksonville, Florida  Produced by Luke Clayton and the team at IncreaseCreative.Co

On this week's episode of the Who Are You? Podcast we sat down Vic Micolucci. Vic is a former news anchor/ investigative reporter for news for jax and has now moved into a new role as the Community Engagement Executive for the Jacksonville sheriff's office. We dove deep into how he got his start in the news world while attending the University of Florida, he tells me about how he was able to bring big youtubers to Jacksonville such as Tommy G and Peter Santenello to do ride alongs with JSO for multiple days so the public can really see what our officers go through on a daily basis, he describes his times of being a volunteer to go help and tell the stories of people who have been affected by hurricanes, we also learn about his love for music and what made him want to start his own DJ/entertainment business, we discuss what have been the most beneficial ways to help the community trust law enforcement and so much more! For more on Vic check out the links belowInstagram- https://www.instagram.com/vicmicolucci/Website- https://www.djvicmic.com/?fbclid=PAZXh0bgNhZW0CMTEAAac5Q9dw3WlUCcBMN0ZUiTnLUTAO0aMKqa5Fvg6uwcd0QVDQM8nzmg8MdkKyzw_aem_FP5fEvtDkwsRW4NAOVkb4g Sponsors: BetterHelpGo to https://betterhelp.com/whoareyou for 10% off your first month of therapy with BetterHelp and get matched with a therapist who will listen and help #sponsored  Make sure to turn on your notifications so you don't miss an episode, please share the episode, leave a like, a review and a 5-star rating. All those things help the podcast be seen by more people!For all business inquires or are interested in being on the show please reach out to me at: whoareyoupod@yahoo.com For all updates and information about the podcast:Instagram: https://www.instagram.com/whoareyoupod/ Facebook: https://www.facebook.com/profile.php?id=100089483824865 TikTok: https://www.tiktok.com/@who.are.you.podca?is_from_webapp=1&sender_device=pc YouTube: https://youtube.com/@whoareyoupod?si=qHi5b7UP28YqrqwU All other links: https://linktr.ee/Whoareyoupod website: https://www.podpage.com/who-are-you/

FOR 1ST SHOW (12:30 PM ET)Description:Join us for JWB's Q2/Q3 2025 Jacksonville Real Estate Market Update. We'll be joined by Gregg Cohen, Co-Founder of JWB Real Estate Capital.Here's what we'll discuss:* Current Jacksonville real estate market pricing, rents, and months of inventory (MOI)* Key trends and updates impacting the Jacksonville market* JWB company stats and Key Performance IndicatorsYou won't want to miss this opportunity to spend some time with one of JWB's owners and learn more about how you can take advantage of the Jacksonville real estate market. Listen NOW!Chapters:00:00 Welcome to the Show!02:00 Introduction to Jacksonville Real Estate Market06:18 The Impact of Interest Rates13:42 Current Market Data Snapshot15:50 Understanding Rent Trends21:17 Historical Context and Future Predictions33:26 Understanding JWB's Internal Metrics33:40 Impressive Growth and Market Performance35:55 Challenges and Opportunities in Property Management37:47 Navigating the Soft Rental Market38:48 The Importance of Long-Term Investment Strategy40:57 The Next Great American Downtown46:59 Revitalizing Downtown Jacksonville50:54 Gateway Jax: A Vision for the Future01:04:17 Q&A Session: Addressing Investor ConcernsStay connected to us! Join our real estate investor community LIVE: https://jwbrealestatecapital.com/nyai/Schedule a Turnkey strategy call: https://jwbrealestatecapital.com/turnkey/ *Get social with us:*Subscribe to our channel  @notyouraverageinvestor  Subscribe to  @JWBRealEstateCompanies  

Weekly Message from Maranatha Church of Jacksonville. Find out more at maranathajax.com

To join the best online community on the planet, join the Dunn and Drew Discord channel at patreon.com/dunnanddrewHosted by Dunn, Drew, and Jack — three friends based in Jacksonville, Florida — this podcast brings you raw, unfiltered takes on the Jacksonville Jaguars, the latest headlines from across the NFL, and hilarious deep dives into everyday lifestyle topics. Whether we're breaking down Trevor Lawrence's performance, roasting bad takes, or giving you our hottest power rankings off the dome, we keep it real with authentic banter and a vibe you won't find anywhere else.Every episode delivers a mix of:Jacksonville Jaguars analysis & game recapsNFL news, fantasy football, and game predictionsSports culture, pop culture, and trending topicsStories from life in Jax, Florida — with laughs, hot takes, and occasional chaosSubscribe now and join the growing community of fans who tune in for one of the most entertaining sports & lifestyle podcasts in the game.

Send me a message Using AI to Post 41 Videos a Week Without Lifting a Finger with Josh RogersIf you're still sitting on the sidelines watching other agents blow up on Instagram, this episode is your wake-up call.I sat down with Josh Rogers, who went from 0 to over 22,000+ Instagram followers in 90 days using a system. Josh is cranking out 41 videos a week while homeschooling 8 kids and still running a high producing sales team in Jacksonville, FL. And the wildest part? Most of the videos aren't even made by him.In this episode, we break down:The exact tech stack Josh is using (HeyGen, ElevenLabs, and ChatGPT)How his VA runs the entire content machineWhat kind of content actually gets views, shares, and DMsHow to use Instagram Stories + polls to generate leads without being salesyAnd why you need to stop waiting until it's “perfect” if you ever want to scalePlus, Josh gives you access to the full system via his free cheat sheet:

Rick Stroud and Steve Versnick on the breaking news that Stu Sternberg is in advanced talks to sell the Tampa Bay Rays to a group headed by Patrick Zalupski as a Letter of Intent has been signed. What does this mean for the future of the Rays, where will a stadium be built and more. Hosted on Acast. See acast.com/privacy for more information.

This episode is a first for Decoder Ring: a live show, recorded at the WBUR Festival in Boston, Massachusetts. Given the setting, we decided to take on a Boston-based cultural mystery: namely, the “Boston movie.” Beginning in the late 1990s and early 2000s, Hollywood has churned out a whole cycle of films drenched in Beantown's particularities, crimes, crops, class conflicts, and accents, from The Departed to The Town. Why does a city smaller than El Paso or Jacksonville loom so large in the cinematic imagination? Why does Boston have a movie subgenre all its own? What makes a Boston movie a Boston movie? With the help of three guests—film critic Ty Burr; Lisa Simmons, founder of the Roxbury International Film Festival; and Boston University linguist Danny Erker—we look closely at the history and heyday of the Boston movie: how The Friends of Eddie Coyle set the template, Good Will Hunting shoved the door wide open, and Mystic River ushered in an imperial phase. We discuss the importance of race and class to the Boston movie and the city itself, the role of homegrown movie stars like Ben Affleck and Mark Wahlberg, and, of course, the best and worst of Boston accents on film. This episode of Decoder Ring was produced by Willa Paskin and Max Freedman. Our team also includes Katie Shepherd and supervising producer Evan Chung. Merritt Jacob is Slate's Technical Director.  If you have any cultural mysteries you want us to decode, please email us at DecoderRing@slate.com, or leave a message on our hotline at 347-460-7281. Films referenced in this episode: The Thomas Crown Affair (1968) Love Story (1970) The Friends of Eddie Coyle (1973) The Brink's Job (1978) The Verdict (1982) Quiz Show (1994) Good Will Hunting (1997) Squeeze (1997) Monument Ave. (1998) The Boondock Saints (1999) Southie (1999) Lift (2001) Blue Hill Avenue (2001) Mystic River (2003) Fever Pitch (2005) The Departed (2006) Gone Baby Gone (2007) The Fighter (2010) The Town (2010) Ted (2012) Ted 2 (2015) Black Mass (2015) Spotlight (2015) Want more Decoder Ring? Subscribe to Slate Plus to unlock exclusive bonus episodes. Plus, you'll access ad-free listening across all your favorite Slate podcasts. Subscribe now on Apple Podcasts by clicking “Try Free” at the top of the Decoder Ring show page. Or, visit slate.com/decoderplus to get access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode is a first for Decoder Ring: a live show, recorded at the WBUR Festival in Boston, Massachusetts. Given the setting, we decided to take on a Boston-based cultural mystery: namely, the “Boston movie.” Beginning in the late 1990s and early 2000s, Hollywood has churned out a whole cycle of films drenched in Beantown's particularities, crimes, crops, class conflicts, and accents, from The Departed to The Town. Why does a city smaller than El Paso or Jacksonville loom so large in the cinematic imagination? Why does Boston have a movie subgenre all its own? What makes a Boston movie a Boston movie? With the help of three guests—film critic Ty Burr; Lisa Simmons, founder of the Roxbury International Film Festival; and Boston University linguist Danny Erker—we look closely at the history and heyday of the Boston movie: how The Friends of Eddie Coyle set the template, Good Will Hunting shoved the door wide open, and Mystic River ushered in an imperial phase. We discuss the importance of race and class to the Boston movie and the city itself, the role of homegrown movie stars like Ben Affleck and Mark Wahlberg, and, of course, the best and worst of Boston accents on film. This episode of Decoder Ring was produced by Willa Paskin and Max Freedman. Our team also includes Katie Shepherd and supervising producer Evan Chung. Merritt Jacob is Slate's Technical Director.  If you have any cultural mysteries you want us to decode, please email us at DecoderRing@slate.com, or leave a message on our hotline at 347-460-7281. Films referenced in this episode: The Thomas Crown Affair (1968) Love Story (1970) The Friends of Eddie Coyle (1973) The Brink's Job (1978) The Verdict (1982) Quiz Show (1994) Good Will Hunting (1997) Squeeze (1997) Monument Ave. (1998) The Boondock Saints (1999) Southie (1999) Lift (2001) Blue Hill Avenue (2001) Mystic River (2003) Fever Pitch (2005) The Departed (2006) Gone Baby Gone (2007) The Fighter (2010) The Town (2010) Ted (2012) Ted 2 (2015) Black Mass (2015) Spotlight (2015) Want more Decoder Ring? Subscribe to Slate Plus to unlock exclusive bonus episodes. Plus, you'll access ad-free listening across all your favorite Slate podcasts. Subscribe now on Apple Podcasts by clicking “Try Free” at the top of the Decoder Ring show page. Or, visit slate.com/decoderplus to get access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode is a first for Decoder Ring: a live show, recorded at the WBUR Festival in Boston, Massachusetts. Given the setting, we decided to take on a Boston-based cultural mystery: namely, the “Boston movie.” Beginning in the late 1990s and early 2000s, Hollywood has churned out a whole cycle of films drenched in Beantown's particularities, crimes, crops, class conflicts, and accents, from The Departed to The Town. Why does a city smaller than El Paso or Jacksonville loom so large in the cinematic imagination? Why does Boston have a movie subgenre all its own? What makes a Boston movie a Boston movie? With the help of three guests—film critic Ty Burr; Lisa Simmons, founder of the Roxbury International Film Festival; and Boston University linguist Danny Erker—we look closely at the history and heyday of the Boston movie: how The Friends of Eddie Coyle set the template, Good Will Hunting shoved the door wide open, and Mystic River ushered in an imperial phase. We discuss the importance of race and class to the Boston movie and the city itself, the role of homegrown movie stars like Ben Affleck and Mark Wahlberg, and, of course, the best and worst of Boston accents on film. This episode of Decoder Ring was produced by Willa Paskin and Max Freedman. Our team also includes Katie Shepherd and supervising producer Evan Chung. Merritt Jacob is Slate's Technical Director.  If you have any cultural mysteries you want us to decode, please email us at DecoderRing@slate.com, or leave a message on our hotline at 347-460-7281. Films referenced in this episode: The Thomas Crown Affair (1968) Love Story (1970) The Friends of Eddie Coyle (1973) The Brink's Job (1978) The Verdict (1982) Quiz Show (1994) Good Will Hunting (1997) Squeeze (1997) Monument Ave. (1998) The Boondock Saints (1999) Southie (1999) Lift (2001) Blue Hill Avenue (2001) Mystic River (2003) Fever Pitch (2005) The Departed (2006) Gone Baby Gone (2007) The Fighter (2010) The Town (2010) Ted (2012) Ted 2 (2015) Black Mass (2015) Spotlight (2015) Want more Decoder Ring? Subscribe to Slate Plus to unlock exclusive bonus episodes. Plus, you'll access ad-free listening across all your favorite Slate podcasts. Subscribe now on Apple Podcasts by clicking “Try Free” at the top of the Decoder Ring show page. Or, visit slate.com/decoderplus to get access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

This episode is a first for Decoder Ring: a live show, recorded at the WBUR Festival in Boston, Massachusetts. Given the setting, we decided to take on a Boston-based cultural mystery: namely, the “Boston movie.” Beginning in the late 1990s and early 2000s, Hollywood has churned out a whole cycle of films drenched in Beantown's particularities, crimes, crops, class conflicts, and accents, from The Departed to The Town. Why does a city smaller than El Paso or Jacksonville loom so large in the cinematic imagination? Why does Boston have a movie subgenre all its own? What makes a Boston movie a Boston movie? With the help of three guests—film critic Ty Burr; Lisa Simmons, founder of the Roxbury International Film Festival; and Boston University linguist Danny Erker—we look closely at the history and heyday of the Boston movie: how The Friends of Eddie Coyle set the template, Good Will Hunting shoved the door wide open, and Mystic River ushered in an imperial phase. We discuss the importance of race and class to the Boston movie and the city itself, the role of homegrown movie stars like Ben Affleck and Mark Wahlberg, and, of course, the best and worst of Boston accents on film. This episode of Decoder Ring was produced by Willa Paskin and Max Freedman. Our team also includes Katie Shepherd and supervising producer Evan Chung. Merritt Jacob is Slate's Technical Director.  If you have any cultural mysteries you want us to decode, please email us at DecoderRing@slate.com, or leave a message on our hotline at 347-460-7281. Films referenced in this episode: The Thomas Crown Affair (1968) Love Story (1970) The Friends of Eddie Coyle (1973) The Brink's Job (1978) The Verdict (1982) Quiz Show (1994) Good Will Hunting (1997) Squeeze (1997) Monument Ave. (1998) The Boondock Saints (1999) Southie (1999) Lift (2001) Blue Hill Avenue (2001) Mystic River (2003) Fever Pitch (2005) The Departed (2006) Gone Baby Gone (2007) The Fighter (2010) The Town (2010) Ted (2012) Ted 2 (2015) Black Mass (2015) Spotlight (2015) Want more Decoder Ring? Subscribe to Slate Plus to unlock exclusive bonus episodes. Plus, you'll access ad-free listening across all your favorite Slate podcasts. Subscribe now on Apple Podcasts by clicking “Try Free” at the top of the Decoder Ring show page. Or, visit slate.com/decoderplus to get access wherever you listen. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week's episode is stacked with the latest from around the NFL and fantasy football.  Jeff Mans begins with some news around NFL minicamps, including a new running back in New Orleans, the Bengals restarting contract talks with sack leader Trey Hendrickson, and a trial date for Vikings WR Jordan Addison. Mans has also uncovered the new fantasy lovechild in the NFL, a player that, no matter how much evidence is produced, the fans and fantasy players are loving unconditionally. Then it is time for Jeff to reveal a few players that he is higher on right now and a few that he is lower on from a fantasy football perspective. This conversation weaves into a ton of information about the new offenses in Chicago, Detroit, Dallas, Seattle, and Jacksonville. There is even a lesser-known soap opera that played out in Houston last season, right in front of all our eyes, that nobody ever knew until the offseason firings happened. Then there is a deep dive on two incredibly similar wide receivers who are near carbon copies of one another, yet one is going in the fifth round while the other is in or around round eight. Remember to share the show with a friend, hit the like, favorite, heart, thumbs up, subscribe, and comment button for this episode!

This week, Caroline and Liz sit down with Jacksonville-based interior designer Andrew Howard: Renowned for his vibrant take on traditional design, Andrew shares his journey from working in his parents' design store to becoming a celebrated designer. The discussion explores how to inject playful elements into traditional spaces, highlighting the significance of color, unexpected accents, and personal touches in creating inviting homes. Andrew also delves into the nitty-gritty of selecting durable, comfortable furniture and the process of designing spaces that reflect individuality. He also previews his new book, set for release in September, and muses on the creative inspiration that fuels his unique projects. Watch this week's episode with images on the Ballard Designs YouTube Channel: https://bit.ly/4jVD0OG What You'll Hear on This Episode: 00:00 Introduction to Ballard Designs Podcast 00:33 Meet Andrew Howard: A Journey in Design 01:40 Design Philosophy: Playful Traditional Interiors 03:20 Creating Unique and Comfortable Spaces 07:53 The Importance of Scale and Comfort 09:48 Exploring Bold Patterns and Colors 12:38 Andrew's New Book and Instagram Insights 24:44 Commercial Design Challenges 30:12 Unexpected Office Takeover 30:55 Kids' Influence on Home Decor 32:40 The Importance of Floor Plans 34:15 Ceiling Design Insights 36:58 Essential Room Elements 38:09 The Captain's Hour Concept 40:21 Painting and Refinishing Woodwork 44:41 Exploring Color in Design 46:06 Personal Home Design Stories 52:17 Dream Project Locations 54:01 Final Thoughts and Farewell Also Mentioned: ⁠⁠⁠⁠ballarddesigns.com⁠⁠⁠⁠⁠⁠⁠ | Shop Now andrewjhoward.com⁠ | Designer Website @andrewjhow | Designer IG Please send in your decorating dilemmas + pictures so we can answer them on an upcoming episode (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠podcast@ballarddesigns.net⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) . And, of course, please subscribe to the podcast if you haven't already in Apple Podcasts or Spotify so you never miss a new episode. Happy Decorating!

H.B. dives into the On Preaching Mailbag to answer your questions! Drop yours in the comments, and it might be featured on a future episode. Subscribe to the Cutting It Straight magazine at https://CutStraight.org Get a new website, unlimited custom graphics, & full-service podcast production services at https://IncreaseCreative.Co/HB Connect with H.B. and access more resources at https://HBCharlesJr.com The On Preaching Podcast is dedicated to helping you to preach faithfully, clearly, and better. Hosted by H.B. Charles, Jr., Pastor-Teacher of Shiloh.Church in Jacksonville, Florida  Produced by Luke Clayton and the team at IncreaseCreative.Co

In week two of In the Arena, Pastor Joby dives into Acts 19 to show us how the same gospel power that dismantled Ephesus's demonic stronghold still fights for us today. Paul didn't bring gimmicks or self-help hacks—he wielded the Spirit to rend magic books worth a fortune, ignite genuine repentance, and spark revival through worship, confession, fellowship, and generosity. But decades later, Ephesus had abandoned its first love. Jesus's tender rebuke—“Do you love me?”—reminds us that our authority flows not from programs or performance, but from a heart rooted in Christ. If you're weary of fighting in your own strength, longing to rekindle passion for Jesus, or ready to wield gospel-fueled weapons against every chain, this sermon will equip you to step into the arena and watch Him move.

Ellen Adair and Eric Gilde discuss the baseball portions of "Twilight." They introduce the film (1:49), with an overview of the story, the cast, and filmmakers, and review the 20-80 baseball scouting grades for rating the film (6:01). Amount of Baseball (10:35) opens with a true conundrum: what is the amount of baseball in the baseball portion of "Twilight"? Do we consider the "first Mariners game" and spring training? Baseball Accuracy (15:30) considers the viability of a four-vampire baseball team and a three-vampire baseball team, with the varying degree of problems that arise. Discussion of vampires' familiarity with John Fogarty's "Centerfield," seventh-wheel vampires, and the Mike Fiers of vampires (?). Ellen has issues with the lack of analytical positioning, and Eric queries the notion of thunder from an aluminum bat. Is Alice tipping her pitches? A brief history of baseball gloves (w/r/t Charlie Waitt, Albert Goodwill Spalding, Bill Doak, Rawlings). Some baserunning headscratchers with Carlisle. There is no spring training in Jacksonville (h/t Meg Rowley), but there ARE spring training/regular season timeline issues in this film. Storytelling (40:11) digs in on the substance of the vampire feud, Ellen's annoyance with the notion of the Cullens as "vegetarians," and Eric's annoyance with the sparkliness. Are they good at baseball? Would putting Bella's hair down really help mask her human scent? Some discussion of the directorial style and costume choices. Score (55:39) addresses the use of Radiohead, the Black Ghosts, Muse, and the squealing guitars. Acting (1:00:03) discusses the performances of Kristen Stewart, Robert Pattinson, Peter Facinelli, Elizabeth Reaser, and Edi Gathegi, with shout-outs to Anna Kendrick and Gil Birmingham. Delightfulness of Catcher (1:04:57) weighs the Moment of Utmost Delight, Elizabeth Reaser's line deliveries, and the matriarch as catcher, while Delightfulness of Announcer (1:07:28) doesn't offer so much. Lack of Misogyny (1:08:01) considers the strength of female players, the film's upgrade over the book, with only a brief foray into the misogyny of the whole premise. No spoilers on the following segments: Yes or No (1:14:20), Six Degrees of Baseball (1:19:52), Favorite Moment (1:22:01) Least Favorite Moment (1:23:50), Scene We Would Have Liked to See (1:26:37), Dreamiest Player (1:28:12), Favorite Performance (1:29:41), Review Thank You (1:30:41) and Next Time (1:32:39). Join Our Discord & Support The Show: PL+ | PL Pro - Get 15% off Yearly with code PODCASTProud member of the Pitcher List Fantasy Baseball Podcast Network